SCHEMBL338364

SCHEMBL338364

CCCCCCCCCCCCCC(=O)N[C@H](C(=O)O)[C@@H](C)O

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FAAH O00519 6/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
MAPK1 P28482 1/20 0.62
NOD1 Q9Y239 3/20 0.55
PLA2G2A P14555 1/20 0.55
PLA2G5 P39877 1/20 0.55
ALDH1A1 P00352 1/20 0.52
ASAH1 Q13510 1/20 0.52
ACER2 Q5QJU3 1/20 0.52
DNM1 Q05193 1/20 0.51
PLA2G2C Q5R387 1/20 0.51
PLA2G10 O15496 2/20 0.51
ASAH2 Q9NR71 1/20 0.50
HSP90AA1 P07900 1/20 0.48
SLC6A5 Q9Y345 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5667184 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1NOD1
SCHEMBL17204243 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1NOD1
SCHEMBL543568 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1NOD1
SCHEMBL17203963 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1NOD1
SCHEMBL8823482 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1NOD1
SCHEMBL7268170 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1NOD1
SCHEMBL25196976 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1NOD1
SCHEMBL11047279 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1NOD1
SCHEMBL7269318 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1NOD1
SCHEMBL11047281 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1NOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097584-B2 Therapeutic mixture comprising insulin, ethylenediamine and an antimicrobial preservative; improved chemical and storage stability NOVO NORDISK A/S (DK) 2012-01-17 US claimed
US-5616552-A FOAM MAINTENANCE AND QUALITY; NONIRRITATING TO SKIN AND HAIR AJINOMOTO CO., INC. (JP) 1997-04-01 US claimed
EP-4662197-A1 METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS BASF SE (DE) 2025-12-17 EP disclosed
CN-113993565-B Injection device with filling level indicator 赛诺菲 2025-04-25 CN disclosed
CN-115431458-B Elastomeric article with embedded electronics and method of making the same 西医药服务有限公司 2025-04-01 CN disclosed
CN-113993561-B Injection device 赛诺菲 2025-03-11 CN disclosed
CN-115025324-B Sensor for a drug delivery device 赛诺菲-安万特德国有限公司 2025-01-24 CN disclosed
WO-2024165426-A1 METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS BASF SE (DE) 2024-08-15 WO disclosed
EP-4414360-A1 METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS BASF SE (DE) 2024-08-14 EP disclosed
CN-118284398-A Cleaning agent composition 味之素株式会社 2024-07-02 CN disclosed
EP-3677275-B1 COMBINATION OF AN INSULIN AND A GLP-1 AGONIST SANOFI AVENTIS DEUTSCHLAND (DE) 2024-06-12 EP disclosed
WO-2023090455-A1 DETERGENT COMPOSITION 味の素株式会社 2023-05-25 WO disclosed
CN-107308442-B Pharmaceutical composition comprising a GLP-1 agonist, insulin and methionine 赛诺菲-安万特德国有限公司 2022-10-18 CN disclosed
CN-104955472-A Fatty acid acylated amino acids for growth hormone delivery NOVO NORDISK HEALTHCARE AG 2015-09-30 CN disclosed
US-20150250882-A1 Fatty Acid Acylated Amino Acids for Growth Hormone Delivery NOVO NORDISK HEALTHCARE AG (CH) 2015-09-10 US disclosed
EP-2908845-A1 FATTY ACID ACYLATED AMINO ACIDS FOR GROWTH HORMONE DELIVERY Novo Nordisk Health Care AG (CH) 2015-08-26 EP disclosed
WO-2014060512-A1 FATTY ACID ACYLATED AMINO ACIDS FOR GROWTH HORMONE DELIVERY NOVO NORDISK HEALTH CARE AG (CH) 2014-04-24 WO disclosed
US-8097584-B2 Therapeutic mixture comprising insulin, ethylenediamine and an antimicrobial preservative; improved chemical and storage stability NOVO NORDISK A/S (DK) 2012-01-17 US disclosed
US-5616552-A FOAM MAINTENANCE AND QUALITY; NONIRRITATING TO SKIN AND HAIR AJINOMOTO CO., INC. (JP) 1997-04-01 US disclosed
EP-0687721-A2 Detergent composition Ajinomoto Co., Inc. (JP) 1995-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150250882-A1 Fatty Acid Acylated Amino Acids for Growth Hormone Delivery GHRHR, GHSR, GHITM FAAH 53/4885MEN1 2160/4885KMT2A 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.